Literature DB >> 17076359

[Summary of the practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners].

M Bouma1, G E H M Rutten, W J C de Grauw, Tj Wiersma, A N Goudswaard.   

Abstract

The practice guideline 'Diabetes mellitus type 2' (second revision) addresses the diagnosis, treatment and management of adults with diabetes mellitus type 2 in general practice. The aim of management is the prevention and treatment of diabetes-related symptoms and complications such as cardiovascular disease, nephro-, retino- and neuropathy. The general practitioner gives the patient education and lifestyle advice and repeats this regularly. In addition, the general practitioner and the patient strive to achieve good glycaemic control. The agent of first choice in the medicinal treatment of all type 2 diabetic patients is metformin. This is continued even after the addition of a sulphonylurea derivative or insulin. This represents a change compared to the previous version of the practice guideline. The indications for thiazolidinediones are limited. To reduce the cardiovascular risk, it is advised to aim at a systolic blood pressure below 140 mmHg. It is also recommended that each patient be prescribed a statin, unless the patient belongs to a subgroup in which the indication for cholesterol lowering therapy is weak or the patient refuses it. Compared to the former guideline, more emphasis is placed on the prevention of nephropathy. The general practitioner is advised to calculate the creatinine clearance yearly and to test for relevant albuminuria in each patient with a life expectancy of 10 years or more. If microalbuminuria is present, the patient is prescribed an angiotensin converting enzyme (ACE) inhibitor, even if the blood pressure is not elevated. The detection of patients with a high risk of diabetic ulcer is also given more emphasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17076359

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  19 in total

1.  Yield of opportunistic targeted screening for type 2 diabetes in primary care: the diabscreen study.

Authors:  Erwin P Klein Woolthuis; Wim J C de Grauw; Willem H E M van Gerwen; Henk J M van den Hoogen; Eloy H van de Lisdonk; Job F M Metsemakers; Chris van Weel
Journal:  Ann Fam Med       Date:  2009 Sep-Oct       Impact factor: 5.166

2.  Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial.

Authors:  Nynke D Scherpbier-de Haan; Gerald M M Vervoort; Chris van Weel; Jozé C C Braspenning; Jan Mulder; Jack F M Wetzels; Wim J C de Grauw
Journal:  Br J Gen Pract       Date:  2013-12       Impact factor: 5.386

3.  Effects of a cognitive behavioural treatment in patients with type 2 diabetes when added to managed care; a randomised controlled trial.

Authors:  Laura M C Welschen; Patricia van Oppen; Sandra D M Bot; Piet J Kostense; Jacqueline M Dekker; Giel Nijpels
Journal:  J Behav Med       Date:  2012-09-29

4.  Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial.

Authors:  S F E Praet; E S J van Rooij; A Wijtvliet; L J M Boonman-de Winter; Th Enneking; H Kuipers; C D A Stehouwer; L J C van Loon
Journal:  Diabetologia       Date:  2008-02-23       Impact factor: 10.122

5.  Vascular outcomes in patients with screen-detected or clinically diagnosed type 2 diabetes: Diabscreen study follow-up.

Authors:  Erwin P Klein Woolthuis; Wim J C de Grauw; Susanne M van Keeken; Reinier P Akkermans; Eloy H van de Lisdonk; Job F M Metsemakers; Chris van Weel
Journal:  Ann Fam Med       Date:  2013 Jan-Feb       Impact factor: 5.166

6.  Short- and long-term effects of a quality improvement collaborative on diabetes management.

Authors:  Loes Mt Schouten; Marlies Ejl Hulscher; Jannes Je van Everdingen; Robbert Huijsman; Louis W Niessen; Richard Ptm Grol
Journal:  Implement Sci       Date:  2010-11-28       Impact factor: 7.327

7.  Web-based guided insulin self-titration in patients with type 2 diabetes: the Di@log study. Design of a cluster randomised controlled trial [TC1316].

Authors:  Mariëlle G A Roek; Laura M C Welschen; Piet J Kostense; Jacqueline M Dekker; Frank J Snoek; Giel Nijpels
Journal:  BMC Fam Pract       Date:  2009-06-09       Impact factor: 2.497

8.  Effects of cardiovascular disease risk communication for patients with type 2 diabetes on risk perception in a randomized controlled trial: the @RISK study.

Authors:  Laura M C Welschen; Sandra D M Bot; Piet J Kostense; Jacqueline M Dekker; Daniëlle R M Timmermans; Trudy van der Weijden; Giel Nijpels
Journal:  Diabetes Care       Date:  2012-08-24       Impact factor: 19.112

9.  Health care providers' perspective on using family history in the prevention of type 2 diabetes: a qualitative study including different disciplines.

Authors:  Suzanne C M van Esch; Wieke H Heideman; Wilmy Cleijne; Martina C Cornel; Frank J Snoek
Journal:  BMC Fam Pract       Date:  2013-03-07       Impact factor: 2.497

10.  Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data.

Authors:  Sabita S Soedamah-Muthu; Johanna M Geleijnse; Erik J Giltay; Daan Kromhout
Journal:  BMJ Open       Date:  2012-10-31       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.